Navigation Links
In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
Date:7/15/2013

BURLINGTON, Mass., July 15, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of a therapy on overall survival and progression-free survival are attributes that most influence surveyed U.S. and European oncologists' prescribing decisions for second-line metastatic colorectal cancer. Clinical data and the opinions of interviewed thought leaders, however, indicate that current and emerging therapies have no advantage over the sales-leader bevacizumab (Genentech/Roche/Chugai's Avastin)/FOLFIRI (5-fluorouracil, leucovorin and irinotecan) on overall survival, one of the greatest unmet needs in second-line metastatic colorectal cancer. However, opinion leaders express optimism that clinical trial data could show that the mechanism of action of Eli Lilly/ImClone's ramucirumab could confer a benefit on progression-free survival.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Decision Base 2013 report entitled As the Second-Line Treatment Setting for Colorectal Cancer Becomes More Crowded, How Will Oncologists and Payers Differentiate Among New Therapies?  finds that surveyed U.S. oncologists would prescribe ramucirumab, in combination with FOLFIRI, to a median of 20 percent of their second-line drug-treated, metastatic colorectal cancer patients. This modest patient share demonstrates the struggle that a new agent will face penetrating the familiarity of Avastin, as well as strong competition from aflibercept (Sanofi/Regeneron's Zaltrap) and regorafenib (Bayer Healthcare's Stivarga), the latter of which is currently used primarily in later lines of treatment.

The findings also reveal that the safety and tolerability of second-line therapies for metastatic colorectal cancer are another important consideration in oncologists' prescribing decisions, as the incidence of colorectal cancer increases with age and, as a result, therapies in this setting have a great impact on the quality of life in an elderly population.  

The report also finds that surveyed managed care organization (MCO) pharmacy directors are receptive to novel therapies that offer an improvement in median overall survival over currently available therapies, but while some emerging therapies hold promise, they are unlikely to match payers' requirements for widespread inclusion on their formularies.

"Avastin in combination with FOLFIRI is currently the most widely used regimen for the second-line treatment of metastatic colorectal cancer," said Decision Resources Business Insights Analyst Dana Gheorghe, Ph.D. "An emerging therapy like ramucirumab will find it difficult to penetrate the already crowded second-line market, given physicians' familiarity with Avastin. However, if ramucirumab can show competitive advantages in efficacy, and safety in Phase III trials, we believe it has the potential to compete strongly following its anticipated launch in 2015."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accelerate Diagnostics Announces Final Terms of Rights Offering
2. Cancer Vaccine Partnering Terms and Agreements
3. Medstrat Posts Documents Confirming Terms Of Dismissal Of Merges Lawsuit
4. On-Demand Reports on Partnering Terms in Healthcare & Pharma Sectors: New Market Research at ReportsnReports.com
5. Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms
6. Amarantus Biosciences and RBCC Outline Terms for NuroPro Parkinsons Blood Test Joint Venture
7. Sonendo Agrees To Terms For Up To $20 Million In Financing
8. Vaccine Partnering Terms and Agreements
9. Managing Healthcare Reform through Effective Engagement with the Government Ecosystem
10. Side Effects Limit Prescription Drug Compliance
11. CHPA Applauds Pennsylvanias Adoption of Real-Time, Stop-Sale Technology, An Effective Tool in the Fight Against Methamphetamine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
Breaking Medicine News(10 mins):